Alternatives to amyloid for Alzheimer's disease therapies—a symposium report
Name
208_Cable_AnnNYAcadSci_20.pdf
Description
Accepted version
Size
245.31 KB
Format
Adobe PDF
Checksum (MD5)
1cf0ed260c5006cda1b68a4dd0feb7af
Author(s)
Cable, Jennifer
Holtzman, David M.
Hyman, Bradley T.
Tansey, Malú Gámez
Colonna, Marco
Kellis, Manolis
Brinton, Roberta D.
Albert, Marilyn
Wellington, Cheryl L.
Sisodia, Sangram S.
Date Issued
May 2020
Journal
Annals of the New York Academy of Sciences
Publisher
Wiley
Citation
Cable, Jennifer et al. "Alternatives to amyloid for Alzheimer's disease therapies—a symposium report." Annals of the New York Academy of Sciences 1475, 1 (May 2020): 3-14 © 2020 New York Academy of Sciences
Version
Author's final manuscript
Abstract
For decades, Alzheimer's disease research has focused on amyloid as the primary pathogenic agent. This focus has driven the development of numerous amyloid-targeting therapies; however, with one possible exception, none of these therapies have been effective in preventing or delaying cognitive decline in patients, and there are no approved disease-modifying agents. It is becoming more apparent that alternative drug targets are needed to address this complex disease. An increased understanding of Alzheimer's disease pathology has highlighted the need to target the appropriate disease pathology at the appropriate time in the disease course. Preclinical and early clinical studies have focused on targets, including inflammation, tau, vascular health, and the microbiome. This report summarizes the presentations from a New York Academy of Sciences' one-day symposium entitled “Alzheimer's Disease Therapeutics: Alternatives to Amyloid,” held on November 20, 2019.
MIT Department
Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1111/nyas.14371
